After the FDA vote: what actually changed for BPC-157, TB-500, KPV, MOTS-c, Semax, DSIP and Epitalon

TL;DR

• Six of seven were recommended, one declined - BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon cleared the committee; Emideltide (DSIP) did not.
• Every vote was narrow - BPC-157, KPV and TB-500 each 8–6 with one abstention, Epitalon 7–4 with one abstention, Semax 8–5 with one abstention, MOTS-c 7–5 with two abstentions; emideltide (DSIP) was rejected 6-7 (six for, seven against) with one abstention.
• FDA's own career scientists recommended against all seven, and the agency identified no human safety studies for KPV, TB-500, MOTS-c or Epitalon - safety unestablished because those studies have not been run, not a finding of harm.
• Each substance was nominated for a specific indication, usually not the one the community discusses - BPC-157 for ulcerative colitis, Epitalon for insomnia, MOTS-c for obesity and osteoporosis.
• An advisory recommendation is nonbinding - HHS Secretary sign-off, a proposed rule, public comment and a final rule are all outstanding, and the FDA may decline at any step. No lawful route to compounding these substances exists via this path today.
• Nothing about legal access changed - as of 19 October 2026 no proposed rule has been published, none of the six is on the final 503A Bulks List, and no interim enforcement policy has been issued. A draft interim policy went to White House (OMB) review on 14 October 2026; its text is not public, and enforcement discretion would list and approve nothing.
• What to watch next - the published text of that interim policy, any proposed rule, and the second PCAC meeting expected before the end of February 2027 (GHK-Cu, LL-37, Dihexa, Melanotan II, PEG-MGF).

Educational content, not medical advice. No doses or protocols appear anywhere; any use is physician-directed. The compounds discussed are investigational and not FDA-approved.

Updated October 2026: outcome re-confirmed as six recommended (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) and Emideltide (DSIP) not recommended, advisory only, nothing on the 503A Bulks List as of 19 October 2026. Adds the 14 October 2026 submission of a draft interim peptide compounding policy to OMB/OIRA review: not issued, text not public, and an enforcement-discretion policy would not list, approve, or cover research-use-only products, supplements or 503B.

Updated 28 September 2026: replaced the rulemaking-timeline estimate ("realistically not before late 2027") with a status statement. Nothing is on the 503A Bulks List; every remaining step is outstanding; no completion date is predicted.

Updated September 2026: the full status line is now stated up front: six peptides recommended (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax), emideltide (DSIP) not recommended, and as of 15 September 2026 nothing has been added to the 503A Bulks List, with notice-and-comment rulemaking and formal approval by the Secretary of Health and Human Services both still outstanding. All six margins are now confirmed, including TB-500 at 8-6 with one abstention, which this page previously withdrew as unconfirmed; Epitalon, Semax and the emideltide rejection move from "reported" to confirmed. The second-meeting section is re-dated and re-framed as a phased review.

Updated September 2026: three vote margins are now independently confirmed (BPC-157 8-6 with one abstention, KPV 8-6 with one abstention, MOTS-c 7-5 with two abstentions) and TB-500's margin is explicitly withdrawn as unconfirmed; adds FDA's own review finding that no human safety studies were identified for KPV, TB-500, MOTS-c or Epitalon; makes the FDA-staff-recommended-against-all-seven finding explicit; and separates the four regulatory states: recommended, listed, reclassified, approved.

Updated September 2026: confirms that as of 3 September 2026 no proposed rule has been published, the six recommended peptides are not on the final 503A Bulks List, and no interim enforcement policy has been announced; adds the nominated/proposed indication for each of the seven substances and why it is rarely the use the community discusses; adds the reported per-substance vote tallies as trade-press figures pending the official minutes; and names HHS Secretary sign-off as a required step in the sequence.

Updated August 2026: sharpens the nonbinding framing and the full docket → proposed rule → comment → final rule sequence, confirms the meeting dates and the six-in-one-out outcome, and adds the published counter-argument against expanding compounded-peptide access.

---

For two years the peptide space has been waiting on this meeting. The headlines that followed it - "FDA panel votes for peptides," "win for RFK Jr." - are broadly accurate and almost useless for making a decision, because they compress a narrow, nonbinding advisory vote into something that sounds like a finish line. It isn't one. Here is the accurate version of what happened on 23 and 24 July 2026, and what it does and doesn't mean if you use these compounds.

The one-line verdict for each of the seven

The Pharmacy Compounding Advisory Committee (PCAC) met over two days - 23 and 24 July 2026 - and voted on whether each peptide should be recommended for the 503A Bulk Drug Substances List, the list that governs what compounding pharmacies may lawfully prepare under Section 503A. Six of the seven cleared the committee; one did not.

Six in, one out. Two features of that table matter more than the individual results. First, every vote was close - there was no landslide for any substance, and the tallies turned on one or two members. All the margins are now confirmed and are set out below. Second, and more remarkably: FDA's own career scientists recommended against adding any of the seven, citing insufficient evidence, and the committee recommended six anyway. Observers described a panel departing that comprehensively from its agency's own review as close to unprecedented. This was a contested vote, not a consensus.

What each substance was actually nominated for

This is the detail almost every summary dropped, and it changes how the results should be read. A substance does not go to the PCAC in the abstract. It arrives attached to a nominated or proposed indication - a specific clinical use that the nomination asks the committee to consider. The committee evaluates the substance against that use, not against everything the internet does with it.

The nominated indication is usually not the use the community discusses. BPC-157 went to the committee as an ulcerative-colitis candidate - not as a tendon-repair one, which is overwhelmingly what it is bought and discussed for. Epitalon was nominated for insomnia, not for the anti-aging and telomere claims that carry its reputation. MOTS-c arrived as an obesity and osteoporosis candidate rather than a general mitochondrial or performance one. If you have been reading the July votes as a committee blessing the thing you were already doing, the docket does not support that reading.

And the more important point sits one level up: a nomination validates no use at all - including the nominated one. Appearing on a docket means somebody asked the question. A favourable vote means an advisory panel thought the substance was a reasonable candidate for pharmacies to compound for that proposed use, subject to everything that still has to happen afterwards. It is not a finding of efficacy, not a finding of safety, and not an endorsement of any off-docket use. The distance between "nominated for ulcerative colitis" and "works for your Achilles" is the entire evidence base, and the vote did not close any of it.

The tallies - now confirmed

Trade coverage published per-substance vote counts within days of the meeting. Those margins are now confirmed, including the one this page previously withheld.

An earlier version of this article withdrew TB-500's margin as unconfirmed and declined to assert one. It is now confirmed at 8–6 with one abstention, in line with BPC-157 and KPV. The complete set confirms rather than complicates the picture already described: no substance cleared by more than a couple of votes, abstentions on every ballot, and the single negative decided by one vote. A committee this evenly divided is a committee whose recommendation the FDA has ample room to decline - particularly when its own reviewers advised against all seven.

What FDA's reviewers actually found

This is the part of the record that makes the narrow margins legible, and it is the agency's own assessment rather than anyone's characterisation of it.

FDA identified no human safety studies at all for KPV, TB-500, MOTS-c or Epitalon. Not thin studies, not equivocal ones - none identified. For the remaining substances, human data existed but was small, with safety reporting frequently incomplete, against proposed indications that are mostly chronic.

Two things follow from that, and they point in different directions. The first is that a favourable committee vote on a substance with no identified human safety studies is a statement about a regulatory framework, not a statement about safety - there was no safety evidence base for the vote to be an endorsement of. The second is that a compounding-eligibility review is not an efficacy trial: the statutory question is narrower than "does this work," and reasonable people applying that narrower standard can land where the committee landed. Both are true. Neither makes the vote a reassurance.

Recommended, listed, reclassified, approved - four different things

These four words get used interchangeably in coverage and they describe four separate states. Keeping them apart is most of the work of reading this story correctly.

• Recommended - an advisory committee voted in favour. Nonbinding. This is what happened in July 2026.
• Listed - the substance actually appears on the final 503A Bulks List, after rulemaking completes. This has not happened for any of the seven.
• Reclassified - a substance moved out of compounding Category 2, as happened for a set of peptides in April 2026. Reclassification is not permission; it removes a bar, it does not grant a licence.
• Approved - FDA approval of a drug product, with validated indications, established dosing and a demonstrated safety and efficacy record. None of these substances is approved, and nothing in the 2026 sequence puts any of them on a path to approval.

A substance can be recommended and not listed, reclassified and not recommended, and all of the above while remaining unapproved. All seven July substances are currently in exactly that position.

DSIP was the exception - and that's instructive

The one negative, Emideltide - the docket name for the substance also referred to as delta sleep-inducing peptide (DSIP) - is worth pausing on, because it's the clearest signal of how the committee weighed evidence. DSIP has a suggestive name and a decades-old research history, but its human data is thin, dated and mixed. If you've read our peptides-for-sleep explainer, this won't surprise you: DSIP has long sat at the investigational, weak-evidence end of the sleep conversation. Two cautions, though. A committee declining to recommend a substance is not an FDA rejection of it, and it isn't a safety finding - the full treatment is in DSIP and the July 2026 vote. And the six substances that were recommended are, legally, in exactly the same position as DSIP today: none of them is lawful to compound on the strength of this vote.

"Recommended" is not "approved" - the road that still follows

This is the part the headlines flatten, and it is the single most important thing to understand.

The PCAC is an advisory committee. It reviews evidence and makes a recommendation. Its votes are nonbinding and did not make any of these peptides lawful for compounding under Section 503A. The FDA retains sole authority over whether a substance is placed on the 503A Bulks List, and it is not obliged to follow the panel - the agency has declined to follow advisory committees before, and here its own reviewers are already on record against these substances.

The sequence that still has to run, in order:

1. Advisory vote - done, 23–24 July 2026. Nonbinding.
2. FDA docket review - the agency considers the recommendation alongside its own scientific review. It may decline.
3. HHS Secretary sign-off - a required step, not a formality. The committee's recommendation and the agency's proposal still need sign-off at HHS Secretary level before the rulemaking can carry it forward. Until that has happened, nothing downstream can.
4. Proposed rule - publication in the Federal Register, if the FDA decides to proceed.
5. Public comment period - anyone may file; comments must be considered.
6. Final rule - only at this point could a substance actually sit on the 503A Bulks List.

Only step one has happened, and as of 19 October 2026 it is still the only step that has happened. Nearly three months after the vote, the FDA has not published a proposed rule. No HHS Secretary sign-off on a listing has been announced, and it is a required step before any of this becomes a rule. Nothing has been added to the 503A Bulks List - the six recommended substances are not on the final list, and no interim enforcement policy has been issued - meaning there is no transitional arrangement under which a pharmacy could lawfully compound them in the meantime. Anyone who tells you the situation shifted over the summer is describing something that did not happen.

Every one of those remaining steps is outstanding, no completion date has been set, and any step along the way can change the outcome. No lawful route to a licensed pharmacy compounding any of these substances exists via this path today.

The October development, briefly. On 14 October 2026 HHS/FDA sent a draft "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs at the White House Office of Management and Budget for review. It is not one of the six steps above and does not replace any of them. It has not been issued, its text is not public, and which peptides it would cover is unknown. Law-firm analysis expects enforcement discretion, possibly via Category 1 of the FDA's interim 503A policy: a statement that the FDA would not plan to act against 503A pharmacies compounding certain peptides for individual patients, under conditions. That would add nothing to the 503A Bulks List and approve nothing, could be withdrawn without notice-and-comment, would not cover research-use-only products, dietary supplements or 503B outsourcing facilities, and would not bind state boards. FDA funding runs under a temporary spending measure through 11 December 2026, which adds timeline risk.

So the honest one-sentence version is the same as it was before the vote, only sharper: the committee has knocked on the door, but the FDA still has to decide whether to open it, and then build the doorway. Nothing about your legal access to any of these compounds changed on 24 July 2026, and nothing has changed since. That is the same timeline we set out in are peptides legal now, which separates the 2026 events - reclassified, recommended, listed, approved - and keeps them from being read as one.

The 23 July four - BPC-157, TB-500, KPV, MOTS-c

For most Vivre-adjacent readers, this is the group that matters. BPC-157 and TB-500 are the recovery pair; KPV sits on the gut-and-skin side; MOTS-c on the mitochondrial side. All four were recommended, all four narrowly.

What that changes for a recovery or gut protocol right now: nothing mechanical. A favourable committee vote does not make grey-market vials verified, and it does not fill the human-evidence gap that still defines these compounds - the preclinical case for BPC-157 and TB-500 in tissue repair is genuinely interesting, but controlled human trials remain absent. What the vote could do, if the FDA chooses to act on it, is contribute to a legitimate, physician-supervised, pharmacy-compounded pathway - the channel that, in principle, protects patients, because it comes with sourcing that can be verified and oversight that watches the cautions.

The 24 July three - Semax, Epitalon, DSIP

The second day covered the cognitive, longevity and sleep candidates. Semax (cognitive) and Epitalon (longevity, pineal/melatonin-rhythm claims) were both recommended; Emideltide (DSIP) was not, as above.

For readers following the longevity peptides, Epitalon clearing the committee is notable - but the same caution applies with extra force here, because Epitalon's bolder anti-aging and telomere claims run well ahead of the human data. A nonbinding recommendation by an advisory panel is a statement about compounding eligibility under a specific proposed use, not a validation of the internet's claims. Our deeper treatment of these compounds sits in the Khavinson peptides - Epitalon and Pinealon.

The serious case against opening this door

The argument we usually make - that a supervised compounding channel pulls people out of the grey market and into oversight - is real, but it is not the only serious position, and it would be dishonest to present it as such.

A published counter-argument (Health Affairs Forefront, 2026, "the FDA advisory committee's vote may open a drug compounding back door") holds that expanding access to compounded peptides without stronger clinical evidence risks legitimising therapies whose risks remain poorly characterised. The concern is structural, not rhetorical: 503A compounding was designed to meet individual clinical needs that approved products can't, not to function as a parallel route to market for substances that have never completed controlled human trials. A pharmacy label confers an air of medical legitimacy that the underlying evidence has not earned; demand can then consolidate around compounds nobody has properly studied, and adverse effects surface late and unsystematically because no trial infrastructure is watching. On that reading, the July votes did not solve the safety problem - they moved it somewhere harder to see.

This is a position held by people who take patient safety seriously, and it is the honest counterweight to the "access steers patients away from the grey market" case. Both things can be true at once: unverified grey-market vials are a present, concrete hazard, and a compounding channel built on preclinical data alone is a genuine regulatory risk. Anyone telling you only one of those is real is selling something. Our own position tries to hold both - supervision and verification where a compound is used at all, and no pretence that a bulks-list placement would substitute for evidence that doesn't exist.

The second docket: the February 2027 PCAC meeting

The July meeting was not the end of the queue, and this is the part most coverage left out entirely. A second PCAC meeting is expected before the end of February 2027, to consider five further bulk drug substances for the 503A list. As of 19 October 2026 the FDA has published no date or time - the meeting is expected within that window, not on a confirmed day - and it has published no stated reason for splitting the peptide review across two meetings. Together the two sittings address twelve of the nineteen peptides placed in Category 2 in 2023: a phased, compound-by-compound review, not a blanket reversal, with each substance evaluated individually against the 503A criteria.

The five substances reported for that docket:

A necessary flag on Melanotan II. Its appearance on a review docket should not be read as a signal of safety, and Vivre does not endorse it. Melanotan II is not a benign compound: it is a non-selective melanocortin agonist with a documented adverse-effect profile, it is widely sold through exactly the unregulated channels this guide warns about, and dermatological concern about pigmented-lesion changes in people using it is long-standing. Being considered by a committee is not a safety finding. If anything, the fact that a substance with that profile is on the docket is the clearest demonstration that "under review" and "safe" are unrelated statements.

The mechanics will be the same as in July: FDA staff present a scientific review first, then the committee votes on a nonbinding recommendation. The final decision belongs to the FDA and may differ from the committee's vote - as it may for the six substances recommended in July. Expect the same headline compression in February 2027 that we saw in July 2026, and apply the same discipline to it.

How the second docket got here

Briefly, because it explains why there is a queue at all. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that many peptides then sitting in compounding Category 2 would be considered for reclassification to Category 1. In April 2026 the FDA acted on part of that, removing a set of peptides from Category 2 following withdrawal of the nominations against them - an event that reopened the question of a supervised compounding channel, and that the July votes then built on. Removal from Category 2 did not, by itself, authorise compounding. The July 23–24 meeting handled the first batch of seven; the next five follow in the second-wave meeting. The full three-event timeline, with dates, is in are peptides legal now.

What the second meeting will and won't change

For the avoidance of doubt, and because it will be misreported: a recommendation at the second meeting will be neither an approval nor a change in legal status on the day it happens - exactly as the July votes were not. Nothing on that docket becomes lawfully compoundable until the FDA accepts a recommendation, HHS Secretary sign-off is given, and notice-and-comment rulemaking completes: proposed rule, public comment, final rule. A favourable vote would start a clock, not stop one. And because the FDA may decline, a favourable vote is not even a guarantee that the clock starts.

What this means if you currently use these compounds

Practically, for the foreseeable stretch, far less changes than the excitement implies.

The July vote does not make any of these peptides an FDA-approved drug. It does not place any of them on the 503A bulks list - that still requires FDA action and rulemaking. It does not make "research use only" vials safe, legal or verified, and it does not change the evidence base: investigational still means investigational. What changed is that six of seven substances now carry a favourable but nonbinding recommendation, which the FDA may still decline.

The reasonable posture is therefore unchanged: patience plus diligence. Follow the rulemaking that may or may not follow, note the second committee meeting as a date on the calendar rather than a deadline, and in the meantime treat sourcing as the thing that actually determines your risk. The regulatory category of a compound tells you far less about your safety than where you got it and who is supervising you. For the durable version of that argument, see are peptides legal now, which peptides are legal in 2026 and the 2026 reclassification explainer, which set up the vote this article now updates.

If you were counting on the vote to change your sourcing

Transitional moments are exactly when the grey market gets loudest - "buy before it's regulated," "get it while it's research-only." The vote gives that pitch a fresh coat of paint and none of the substance, and the second docket will hand it another. That framing is worth naming for what it is: an urgency device, not a reason. Enforcement in 2026 has escalated from warning letters to criminal charges, including a multi-year federal prison sentence in August 2026 for a research-peptide seller who admitted forging his own certificates of analysis; vendors have disappeared overnight, which is its own supply risk for anyone mid-course. A committee recommendation does not immunise anyone selling into the grey market, and it does not turn a legal disclaimer into a safety guarantee. We are not going to hand you a checklist for grading sellers - that exercise reads as a specification to the people it is meant to warn you about, and it puts the burden in the wrong place. The durable answer is the boring one: work inside a supervised channel, and route the question to a prescriber who can take clinical responsibility for what you are given.

What Vivre is doing

Nothing about our position changes with the vote, because our position was never contingent on it. Vivre operates only within compliant channels - which is why a clearer regulatory path for compounds like BPC-157, TB-500, KPV and MOTS-c could be good for patients, and why the Health Affairs objection above deserves a hearing rather than a rebuttal. Until a path is actually finalised through rulemaking, our answer is the one it has always been: measurement first, verified product always, and honesty about what the evidence does and doesn't show. Supervised access is not changing because of a headline, and we will not encourage anyone to accumulate product ahead of a rule that doesn't exist. That applies equally to the second docket - including, emphatically, to Melanotan II, which we would not offer regardless of how that committee votes.

Frequently asked questions

Did the FDA approve BPC-157? No. On 23 July 2026 an FDA advisory committee recommended BPC-157 for the 503A compounding list in a narrow, nonbinding vote. That is not FDA approval, and it does not place BPC-157 on the bulks list - that would require HHS Secretary sign-off, then FDA notice-and-comment rulemaking: proposed rule, public comment, final rule. None of those steps has happened. Note too that BPC-157 was nominated for ulcerative colitis, not tendon repair - the vote says nothing about the use it is most often bought for.

What were these peptides nominated to treat? Each arrived on the docket attached to a proposed indication: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Epitalon for insomnia, and Semax for selected neurologic uses. Emideltide (DSIP) was the sleep candidate and was not recommended. In most cases the nominated indication is not the use discussed in the community - and a nomination validates no use at all, including the nominated one.

What were the actual vote counts? All are now confirmed: BPC-157 8–6 with one abstention, KPV 8–6 with one abstention, TB-500 8–6 with one abstention, MOTS-c 7–5 with two abstentions, Epitalon 7–4 with one abstention and Semax 8–5 with one abstention. Emideltide (DSIP) was rejected 7–6 with one abstention. An earlier version of this page withheld TB-500's margin as unconfirmed; it is now confirmed. The pattern - narrow margins, abstentions on every ballot, and a committee going against its own agency's reviewers - is the durable point, not the digits.

Did FDA's own scientists support this? No. FDA's career scientists recommended against adding any of the seven substances, citing insufficient evidence. The advisory committee recommended six anyway. Observers described a departure that comprehensive as close to unprecedented. FDA also identified no human safety studies for KPV, TB-500, MOTS-c or Epitalon.

Are peptides legal after July 2026? The legal status of these compounds did not change on the vote dates and has not changed since. The committee's recommendations are nonbinding inputs to a future FDA rulemaking process, and FDA retains sole authority over the 503A list. Until that process concludes, nothing about lawful access has changed, and "research use only" sales remain what they were. A draft interim enforcement policy has been at White House (OMB) review since 14 October 2026; it has not been issued, and even if issued it would not reach research-use-only products. See are peptides legal now for the dated version.

Which peptide was not recommended? Emideltide - also referred to as DSIP (delta sleep-inducing peptide) - was the only one of the seven the committee voted against, and narrowly. The other six (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) were recommended. A committee declining to recommend a substance is not an FDA rejection of it.

Is there a serious argument against all this? Yes, and it deserves to be taken seriously. Commentators writing in Health Affairs Forefront have argued that widening compounded-peptide access without stronger clinical evidence risks legitimising therapies whose risks are still poorly characterised - effectively creating a back door around the evidence standards that approval exists to enforce. See the section above.

Which peptides are on the next PCAC docket? Five are reported: Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and Pegylated Mechano Growth Factor (PEG-MGF). The committee is expected to reconvene before the end of February 2027; as of 19 October 2026 the FDA had published no date, and no stated reason for splitting the review across two meetings. Inclusion on a docket is not an endorsement - Melanotan II in particular carries a real adverse-effect profile and is not a compound Vivre endorses.

Will my current protocol change because of the vote? Not because of the vote itself. If and when rulemaking creates a compliant compounding pathway, supervised access may become more straightforward - but that's a future step, not a present one. Any change to a protocol should come from your physician, not a regulatory headline.

When does anything actually change? There is no date, and it may not happen at all. The FDA must decide whether to accept the recommendations, then issue a proposed rule, take public comment, and finalise, with the option to decline at any point. As of 19 October 2026 none of those steps has happened. A draft interim policy now at White House (OMB) review is a separate, non-rulemaking track; it has not been issued and would not place anything on the list. A second committee meeting expected before the end of February 2027 adds five more candidates to the same slow pipeline; it does not accelerate the first seven.

---

Where Vivre stands

The vote is a milestone, not a verdict. A committee recommended six of seven substances and declined one, over the objection of FDA's own scientists, by margins of one or two votes - which is a genuine signal about where the debate is heading and a poor basis for changing what you put in your body this month. The compounds that were reviewed are the same compounds today that they were in June: investigational, largely lacking controlled human trials, and only as safe as their sourcing and supervision. The same will be true of the five substances reviewed at the second meeting, on the day after it as on the day before.

If you're weighing any of these compounds, the right first step isn't reacting to a rule change that hasn't happened - it's a conversation with a physician who will read the evidence at its real weight.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore BPC-157.

Related reading

• Are peptides legal now? The 2026 timeline, untangled · The 2026 FDA peptide reclassification, explained · Which peptides are legal in 2026 · DSIP and the July 2026 vote · The Khavinson peptides - Epitalon and Pinealon · How to choose a trustworthy peptide source · Thymosin alpha-1: what the evidence supports · PEG-MGF: the fifth name on the next FDA docket
• Part of The Complete Guide to Peptides

---

Educational content, not medical advice. The compounds discussed are investigational and not FDA-approved; PCAC recommendations are nonbinding and do not change legal access. Recommended is not approved. Physician-directed use and verified product only; do not self-source peptides. Vivre does not endorse Melanotan II. Claims for the Malaysian market are subject to MAB requirements. This article reflects the 23–24 July 2026 advisory-committee votes and the expected second-wave meeting, and will be updated as the FDA acts.

References

• FDA Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026, on peptide bulk drug substances for the 503A Bulks List - FDA advisory committee calendar (https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026). · 23 July: the committee discussed BPC-157-related (free base / acetate), KPV-related, TB-500-related and MOTS-c-related substances. · 24 July: Emideltide - also referred to as delta sleep-inducing peptide (DSIP) - plus Semax-related and Epitalon-related substances. · Outcome: the committee voted in favour of BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and against recommending Emideltide (DSIP). Six in, one out. · Confirmed tallies: BPC-157 8–6 with one abstention; KPV 8–6 with one abstention; TB-500 8–6 with one abstention; MOTS-c 7–5 with two abstentions; Epitalon 7–4 with one abstention; Semax 8–5 with one abstention; emideltide (DSIP) rejected 7–6 with one abstention. An earlier version of this file withdrew TB-500's margin as unconfirmed and treated Epitalon, Semax and the emideltide rejection as trade-press figures; all are now confirmed. · FDA's own career scientists recommended against adding any of the seven substances, citing insufficient evidence; the committee recommended six anyway, a departure observers described as close to unprecedented. · FDA identified no human safety studies for KPV, TB-500, MOTS-c or Epitalon. Sources: AJMC; NCPA (31 July 2026); Health Affairs Forefront; FDA briefing document; RAPS; McDermott Will & Emery. · Four distinct regulatory states - recommended / listed / reclassified / approved - must be kept separate. · Nominated/proposed indications on the docket: BPC-157 - ulcerative colitis; KPV - wound healing and inflammatory conditions; TB-500 - wound healing; MOTS-c - obesity and osteoporosis; Epitalon - insomnia; Semax - selected neurologic uses. A nomination is a request for consideration and validates no use, including the nominated one. · HHS Secretary sign-off is a required step before rulemaking can carry a recommendation forward; it had not been given as of 15 September 2026. · The PCAC is advisory; its votes are nonbinding and did not make any of these peptides lawful for compounding under Section 503A. FDA retains sole authority over placement on the 503A Bulks List. Remaining sequence: advisory vote → FDA docket review → proposed rule → public comment period → final rule. Nothing had changed legally as of 19 October 2026: no proposed rule published, nothing added to the 503A Bulks List, no interim enforcement policy issued. · Draft "Interim Access Policy for Compounding Using Certain Peptides" submitted to OIRA/OMB for review on 14 October 2026; not issued, text not public; expected enforcement-discretion / Category 1 mechanism; would not cover research-use-only products, dietary supplements or 503B, and would not bind state boards - Holland & Knight, "Peptides at a Crossroads" (October 2026) (https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know); Buchanan Ingersoll & Rooney, 16 October 2026 (https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know); Becker's Hospital Review, 15 October 2026 (https://www.beckershospitalreview.com/glp-1s/hhs-sends-peptide-compounding-plan-to-white-house-5-things-to-know/). Status only: each remaining step is outstanding and FDA may decline; no completion date is asserted here. · Regulatory analysis: Buchanan Ingersoll & Rooney, "FDA PCAC Recommends Six Peptides for the 503A Bulks List: What Compounding Pharmacies Need to Know" (https://www.bipc.com/fda-pcac-recommends-six-peptides-for-the-503a-bulks-list-what-compounding-pharmacies-need-to-know) and "FDA Voted Yes on Six Peptides - Now What? The Regulatory Road Ahead" (https://www.bipc.com/fda-voted-yes-on-six-peptides-now-what-the-regulatory-road-ahead). · Counter-argument: Health Affairs Forefront (2026), "FDA Advisory Committee's Vote May Open Drug Compounding Back Door For Unapproved Peptides" (https://www.healthaffairs.org/content/forefront/fda-advisory-committee-s-vote-may-open-drug-compounding-back-door-unapproved-peptides) - expanding compounded-peptide access without stronger clinical evidence risks legitimising therapies whose risks remain poorly characterised. · Second-wave PCAC meeting expected before the end of February 2027, reported to cover five bulk drug substances: Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF; no date or time published as of 19 October 2026, and no stated reason published for splitting the review across two meetings - do not cite either. The two meetings together address twelve of the nineteen peptides placed in Category 2 in 2023; each compound is evaluated individually against the 503A criteria. Procedure: FDA staff scientific review precedes the committee vote; the final decision rests with FDA and may differ from the committee recommendation. · Background: HHS Secretary Robert F. Kennedy Jr. announced in February 2026 that many Category 2 peptides would be considered for reclassification to Category 1; in April 2026 the FDA removed a set of peptides from Category 2 following withdrawal of the nominations - removal from Category 2 does not authorise compounding. · Contemporaneous reporting: STAT News, TIME, NBC News, Fierce Pharma, RAPS, FDA Law Blog (July 2026). · All dates and tallies to be re-verified against the Federal Register and FDA meeting minutes before publication.